

**FOI 1516 193**

**Summary Issue: Medicines Management**

**This information relates to Bristol Clinical Commissioning Group**

<b>Question</b>	<b>Response</b>
1) We understand the CCG has representation on the following medicines management / prescribing / formulary committees:  Please confirm if this is correct.	
Avon and Wiltshire Mental Health Partnership NHS Trust Drug and Therapeutics Group	The Head of Medicines Management at South Gloucestershire CCG attends the AWP formulary meetings (Medicines Optimisation Group) on behalf of Bristol CCG, North Somerset CCG, and South Gloucestershire CCG.
The Bristol, North Somerset, and South Gloucestershire (BNSSG) Joint Formulary Group	Yes – a number of Bristol CCG staff attend this.

<b>Question</b>	<b>Response</b>
2) Does the CCG have representation on any other medicines management / prescribing / formulary committees? If so, please advise which	Representation on the BNSSG Drug & Therapeutics Committee, North Bristol NHS Trust Drug & Therapeutics Committee, North Bristol NHS Trust Medicines Governance Group, and the University Hospitals Bristol NHS Foundation Trust Medicines Advisory Group.

Question	Response
3) Does the CCG take a lead role on any of the above committees? If so, please advise which.	Yes. The Interface Pharmacists at Bristol CCG manage and coordinate the BNSSG Joint Formulary Group and the BNSSG Drug & Therapeutics Committee.

Question	Response
4) If the CCG does not take a lead role, please advise which CCGs take lead roles on the above committees.	NA

Question	Response
5) Does the CCG, or any of the above committees on which it sits, reference a regional drug evaluation body (RDEB) for advice when determining products for formulary inclusion (such as London Medicines Evaluation Network, Wolfson Institute, a regional medicines information service etc)? If so, please advise which RDEB/s	<p>Yes. We use the following:</p> <ul style="list-style-type: none"> <li><input type="checkbox"/> AWMSG – All Wales Medicines Strategy Group</li> <li><input type="checkbox"/> LNDG – London New Drugs Group</li> <li><input type="checkbox"/> MTRAC – Midland Therapeutic Review &amp; Advisory Committee</li> <li><input type="checkbox"/> NETAG / NTAG – North East / Northern Treatment Advisory Group</li> <li><input type="checkbox"/> NICE – National Institute for Health and Care Excellence</li> <li><input type="checkbox"/> NICE-ES – NICE Evidence Summary</li> <li><input type="checkbox"/> NSRIC – NIHR Horizon Scanning Research &amp; Intelligence Centre</li> <li><input type="checkbox"/> RDTC – Regional Drug &amp; Therapeutics Centre</li> <li><input type="checkbox"/> SMC – Scottish Medicines Consortium</li> <li><input type="checkbox"/> UKMi – United Kingdom Medicines Information</li> </ul> <p>When completing our own critical evaluations of new medicines, we would look to</p>

	see if these bodies have produced any information in the first instance and reference these in our report.
--	--

<b>Question</b>	<b>Response</b>
6) Which organisation / committee's advice takes precedence when making local formulary decisions (RDEB or medicines management / prescribing / formulary committee)?	The BNSSG Joint Formulary Group takes precedence and will make a decision on behalf of Bristol CCG, North Somerset CCG, South Gloucestershire CCG, North Bristol NHS Trust, University Hospitals Bristol NHS Foundation Trust and Weston Area Healthcare NHS Trust.

<b>Question</b>	<b>Response</b>
7) We have the following formularies listed as used by the CCG:  Avon and Wiltshire Mental Health Partnership NHS Trust (AWP) Formulary The Bristol, North Somerset & South Gloucestershire (BNSSG) Joint Adult Formulary  Please confirm if this is correct and if not, please provide a link/copy of relevant formularies.	Yes. All prescribing within BNSSG should adhere to the BNSSG Joint Formulary; however we do work closely with AWP staff on formulary matters.

<b>Question</b>	<b>Response</b>
8) Are any of the above formularies dominant when making prescribing decisions or does this depend on therapy area?	The BNSSG Joint Formulary Group takes precedence.

Question	Response
9) If dependent on therapy area, please advise which formulary is dominant when making prescribing decisions for diabetes products.	Not dependent on therapy area.

Question	Response
10) Does your CCG work with any other CCGs as a federation? If so, which CCGs.	Bristol CCG works with South Gloucestershire and North Somerset CCGs jointly in the development of the formulary.

Question	Response
<p>We request permission to re-use as a part of an independent analysis into regional drug evaluation boards, which has been commissioned by one of our clients. The contents of the report <b>will not</b> be made available publically, but may be used by other organisation entities and service suppliers. The information in the report will be presented in a factual manner with all publication details staying true to the publisher.</p>	<p>This information is licensed under the Open Government Licence v1.0. To view this licence, visit <a href="http://www.nationalarchives.gov.uk/doc/open-government-licence">www.nationalarchives.gov.uk/doc/open-government-licence</a> or write to the Information Policy Team, The National Archives, Kew, Richmond, Surrey, TW9 4DU.</p> <p>Any enquiries regarding this publication should be sent to: <a href="mailto:contactus@bristolccg.nhs.uk">contactus@bristolccg.nhs.uk</a> or write to FOI Manager, Bristol CCG, South Plaza, Marlborough Street, Bristol, BS3 5AQ</p> <p>When you use this information under the Open Government Licence, you should include the following attribution: Bristol Clinical Commissioning Group, published2nd</p>

	November 2015
--	---------------

The information provided in this response is accurate as of Monday 2<sup>nd</sup> November 2015